Can visual standardized quantification of LGE help doctors see heart scarring better in hypertrophic cardiomyopathy?
In hypertrophic cardiomyopathy (HCM), heart scarring seen on MRI as late gadolinium enhancement (LGE) helps predict risk. A new method called Visual Standardized Quantification of LGE (VISTAQ) makes it easier and more consistent for doctors to measure scarring without special software or manual tracing. Research shows VISTAQ is highly reproducible and works well compared to standard techniques.
What the research says
A multicenter study of 400 patients (250 with HCM) developed VISTAQ, which divides each heart segment into mini-segments and classifies LGE visually 1. In 250 HCM patients, VISTAQ showed excellent reproducibility (intraclass correlation coefficients up to 0.98) across different doctors 1. It was also compared to conventional methods (like mean+2SD, FWHM) in 100 HCM patients and performed well 1. Over a 5-year follow-up in 250 HCM patients, VISTAQ helped predict outcomes 1. Another review notes that cardiac MRI with LGE is key for tissue characterization in HCM, typically showing patchy mid-wall fibrosis 8. While VISTAQ specifically aids LGE quantification, other imaging advances like deep learning models also improve HCM assessment 4.
What to ask your doctor
- Is VISTAQ available at our center for measuring LGE scarring in my HCM?
- How does VISTAQ compare to other LGE quantification methods for my risk assessment?
- What does my LGE burden mean for my long-term outlook and treatment?
- Should I have a cardiac MRI with LGE to evaluate scarring?
- Are there any other imaging tests that might help clarify my condition?
This question is drawn from common patient questions about Cardiology and answered using cited medical research. We do not provide individualized advice.